Abstract:Objectives Dipeptidyl peptidase-4 (DDP-4) inhibitors were considered as an effective treatment choice in patients with type 2 diabetes and renal insufficiency,while its safety and tolerability still needed more confirmation.We performed A systematic review of the safety and efficiency of DDP-4 inhibitors in treatment of patients with type 2 diabetic with chronic kidney disease (CKD) were performed by Meta-analysis.Methods A systemic review of randomized controlled triALs (RCTs) on DPP-4 inhibitors (including sitagliptin,saxagliptin,vildagliptin,linagliptin and teneligliptin) in type 2 diabetes with renal insufficiency was conducted.MEDLINE and EMBASE were searched until June 2015.RCTs or quasi-RCTs comparing the efficacy and/or safety outcome between DPP-4 inhibitors and placebo or an antihyperglycemic agent in diabetes patients with chronic renal disease were selected.Results In 13 evaluated articles,DPP-4 inhibitors lowered hemoglobin A1c (HbA1C) significantly.Subgroup of DPP-4 inhibitor VS Placebo resulted in a more obvious effect on HbA1 c,while subgroup analysis among both patients with moderate and severe renal impairment including ESRD and dialysis still showed significant effect to decrease HbA1 c (％);DPP-4 inhibitors showed little effect on FPG,even compared with placebo(P =O.86,I2 =90％);For safety evaluation,DPP-4 inhibitors slightly increased risk of hypoglycemia (OR [95％ CI]:1.38 [1.07,1.78],P =0.01,I2 =0％) compared with placebo,while the risk decreased when compared with other hypoglycemic agents (OR[95％CI]:0.46 [0.33,0.65],P ＜0.0001,I2 =31％).No significant difference in hypoglycemia was observed in both subgroups of moderate renal impairment and severe renal impairment including ESRD.Total AEs in DPP-4 inhibitor group also showed no difference compared with control,further analysis based on renal function also resulted in a similar effect without significant difference for moderate renal impairment subgroup and in severe renal impairment including ESRD and dialysis group;Similar odds risk were observed in drug related adverse events (OR[95％ CI]:0.93 [0.71,1.22],P =0.6,I2 =7％)and death(OR[95％CI]:0.77 [0.47,1.26],P =0.3,I2 =0％) between DPP-4 inhibitors and control.Conclusions DPP-4 inhibitors are effective to reduce A1C with comparable safety profiles in diabetes patients with moderate to severe renal deficiency including ESRD and dialysis compared to placebo,while evidences from more controlled trials concentrating on particular population of patients with renal deficiency including dialysis are needed.

The efficacy and safety of Diptptidyl peptidase-4 inhibitors combined with insulin in patients with autoimmune diabetes: A updated meta-analysis

Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis.

Dpp-4 Inhibitor Treatment in Chinese Type 2 Diabetes Patients: A Meta-Analysis

Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials

Dipeptidyl Peptidase-4(Dpp-4) Inhibitors: Promising New Agents for Autoimmune Diabetes

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Maintains Β-Cell Function in Patients with Recent-Onset Latent Autoimmune Diabetes in Adults: One Year Prospective Study.

Efficiency and safety of DDP-4 inhibitor in treatment of type 2 diabetes with moderate and severe renal insufficiency: a systemic review and Meta-analysis

Meta-analysis of HbA1c-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Combination with Insulin in T2DM Patients

Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis

Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis

Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis2DPP-4β：meta.

DPP-4 Inhibitors As Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Effects Of Dipeptidyl Peptidase-4 Inhibitors In Type 2 Diabetes Patients With Moderate To Severe Chronic Kidney Disease: Meta-Analysis Of Randomized Controlled Trials Using Unadjusted Data

Altered T‐cell Subsets and Transcription Factors in Latent Autoimmune Diabetes in Adults Taking Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor: A 1‐year Open‐label Randomized Controlled Trial

Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

SGLT2 Inhibitor Plus DPP‐4 Inhibitor As Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta‐analysis

Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review

Islet Function And Insulin Sensitivity In Latent Autoimmune Diabetes In Adults Taking Sitagliptin: A Randomized Trial

The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.

Efficacy and Tolerability of Sitagliptin and Metformin Compared with Insulin As an Initial Therapy for Newly Diagnosed Diabetic Patients with Severe Hyperglycaemia